FIELD: medicine.
SUBSTANCE: present invention relates to immunology. Proposed are variants of the antibody comprising two different pairs of heavy/light chains, one of which recognizes and binds the β-amyloid protein. Nucleic acid molecule, an expression vector and a cell are proposed to produce the antibody. In addition, described is the use of the antibody for preparing a medicament, a pharmaceutical composition and methods for preventing, treating or ameliorating effects of amyloidosis, and also a method for impaired aggregation of previously formed beta-amyloid fibers and a method for preventing neuronal degradation. Reviewed is a method for diagnosing amyloidosis in a patient, a method for determining the concentration of amyloidogenic patches, and a kit for determining and diagnosing amyloid associated diseases and conditions.
EFFECT: according to the invention, the antibodies can be used in the therapy and diagnosis of Alzheimer's disease and other diseases associated with amyloidosis.
61 cl, 18 dwg, 9 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTIBODY TO BETA AMYLOID | 2007 |
|
RU2498999C2 |
| HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
| HUMANISED ANTIBODIES TO AMYLOID BETA | 2008 |
|
RU2567151C2 |
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
| USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2542967C2 |
| METHODS AND COMPOSITIONS FOR TREATMENT OF AMYLOIDOSES | 2018 |
|
RU2746812C1 |
| PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY | 2008 |
|
RU2523894C2 |
| CHIMERIC ANTIBODIES FOR TREATMENT OF DISEASES CHARACTERIZED BY AMYLOIDE DEPOSITION | 2018 |
|
RU2746325C1 |
| HUMANIZED MONOCLONAL ANTIBODY AGAINST Aβ AND ITS USE | 2020 |
|
RU2783528C1 |
| ANTI-AMYLOID BETA (A BETA) 1-42 MONOCLONAL ANTIBODIES POSSESSING THERAPEUTIC PROPERTIES | 2006 |
|
RU2551782C2 |
